FDA Delays Teplizumab License Application
ADC评论
July 6, 2022
RED BANK, N.J., June 30, 2022 /PRNewswire/ — Provention Bio, Inc. (Nasdaq: PRVB) (the “Company”), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases,
